Tag Archives: Treatment

‘Gut bugs’ can drive prostate cancer growth and treatment resistance

Common gut bacteria can fuel the growth of prostate cancers and allow them to evade the effects of treatment, a new study finds. Scientists revealed how gut bacteria contribute to the progression of advanced prostate cancers and their resistance to hormone therapy — by providing an alternative source of growth-promoting androgens, or male hormones. Hormone… Read More »

FDA Approves Qulipta (atogepant) Oral CGRP Receptor Antagonist for the Preventive Treatment of Migraine

[unable to retrieve full-text content]NORTH CHICAGO, Ill., Sept. 28, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Qulipta (atogepant) for the preventive treatment of episodic migraine in adults.1 Qulipta is the first… Drugs.com – New Drug Approvals

A ‘Pacemaker for the Brain’: No Treatment Helped Her Depression — Until This

Advertisement Continue reading the main story Supported by Continue reading the main story A ‘Pacemaker for the Brain’: No Treatment Helped Her Depression — Until This It’s the first study of individualized brain stimulation to treat severe depression. Sarah’s case raises the possibility the method may help people who don’t respond to other therapies. Read… Read More »

Best supplement for menopause: Medical experts agree on their favourite go-to treatment

“Dehydration can exacerbate menopausal symptoms including joint pain and a build-up of uric acid which can contribute to inflammation,” said Dr Hughes. “Drinking plenty of water also helps to retain joint flexibility,” added Dr Henderson. As for exercise, Dr Henderson highlighted how staying active strengthens the muscles and helps a person to get into shape,… Read More »

FDA Approves Livmarli (maralixibat) for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

[unable to retrieve full-text content]FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 29, 2021– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Livmarli (maralixibat) oral solution for… Drugs.com – New Drug Approvals